The clinical stakes are considerable. In children, hypercalcemia can present anywhere along a spectrum from an incidental laboratory finding to vomiting, dehydration, lethargy, hypertension, arrhythmia, acute kidney injury, nephrocalcinosis, or failure to thrive. While primary hyperparathyroidism and malignancy dominate the adult landscape, the causes in neonates, infants, and toddlers skew differently: nutritional excess, vitamin D metabolic disorders, renal phosphate-handling defects, calcium-sensing pathway disorders, subcutaneous fat necrosis, and syndromic disease all demand earlier consideration. The editorial is explicitly framed as an expert-informed triage aid rather than a formal guideline, and its authors stress that outcome-validated studies are still needed.

The framework’s first decision point is deceptively basic: is this really hypercalcemia, and how severe is it? Confirmation and severity assessment should proceed in parallel with stabilization. Total calcium must be interpreted alongside serum albumin, and corrected or ionized calcium may be needed—particularly when albumin is abnormal, acid–base disturbance is present, or the child is critically ill. The authors emphasize that pediatric calcium reference intervals are age-dependent, and that adult-derived ranges may misclassify infants and young children. As practical severity prompts, albumin-adjusted total calcium above 10.5 mg/dL (2.60 mmol/L) or ionized calcium above 5.25 mg/dL (1.32 mmol/L) supports true hypercalcemia, while values approaching or exceeding 12–14 mg/dL (3.00–3.50 mmol/L), rapidly rising calcium, or hypercalcemia accompanied by dehydration, altered mental status, arrhythmia, severe vomiting, renal dysfunction, or nephrocalcinosis should trigger immediate supportive care while the diagnostic workup continues.

That initial evaluation should include serum albumin, iPTH, phosphate, magnesium, alkaline phosphatase, creatinine, 25-hydroxyvitamin D, and a spot urinary calcium-to-creatinine ratio (UCa/UCr). During acute management, calcium, phosphate, magnesium, creatinine, fluid balance, urine output, and clinical status should be reassessed serially, with electrocardiographic monitoring when hypercalcemia is moderate to severe or when symptoms, arrhythmia, renal dysfunction, or relevant electrolyte abnormalities are present. A focused history matters too: calcium or exogenous vitamin D exposure, formula preparation, parenteral nutrition, medications, immobilization, malignancy, renal or transplant history, and family history can all reshape the differential. Renal ultrasonography is useful when hypercalcemia persists, hypercalciuria or renal impairment is present, nephrolithiasis or nephrocalcinosis is suspected, or onset is in infancy.

On the treatment side, isotonic saline is usually first-line for significant or symptomatic hypercalcemia, restoring intravascular volume and promoting renal calcium excretion—though fluid overload must be watched in children with renal or cardiac disease. Notably, the authors caution against routine loop diuretics; if used, they should follow volume restoration and close electrolyte monitoring, and are mainly reserved for fluid overload after euvolemia is achieved. Calcitonin acts rapidly but briefly; glucocorticoids are most useful for vitamin D-mediated or granulomatous disease; and bisphosphonates offer more sustained effects but carry risks of delayed onset, hypocalcemia, renal toxicity, and prolonged skeletal retention in children. In potentially transient infantile conditions such as subcutaneous fat necrosis, bisphosphonates should generally be reserved for severe, prolonged, or persistent hypercalcemia refractory to aggressive hydration and calcitonin. Dialysis remains a last resort for life-threatening or refractory cases, particularly with renal failure or fluid intolerance. Importantly, the authors note that improvement after hydration does not establish dehydration as the underlying cause.

The framework’s central biochemical hinge is iPTH, and the authors deliver a memorable warning: in true hypercalcemia, parathyroid hormone should be suppressed, so a value reported as “normal” may actually be inappropriate if calcium is elevated. Suppressed iPTH points toward iPTH-independent hypercalcemia—vitamin D intoxication or impaired vitamin D catabolism, malignancy, granulomatous disease, immobilization, subcutaneous fat necrosis, medication-related causes, and selected genetic or syndromic disorders. A non-suppressed, inappropriately normal, or elevated iPTH raises concern for iPTH-dependent disease, including primary hyperparathyroidism, familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, multiple endocrine neoplasia-related disease, and tertiary hyperparathyroidism. If the phenotype and iPTH result are discordant, repeat testing after stabilization is reasonable, since biotin exposure, assay differences, renal dysfunction, and sampling after treatment can all complicate interpretation.

Age then becomes the lens through which iPTH-independent causes are prioritized. In neonates, infants, and young toddlers, clinicians should first revisit intake and exposure, because excess vitamin D or calcium is reversible and easily missed. If exposure does not explain the picture, inherited or syndromic disease should be considered early—especially when hypercalcemia is persistent, recurrent, or accompanied by hypercalciuria, hypophosphatemia, nephrocalcinosis, or a positive family history. CYP24A1- and SLC34A1-related disease and Williams–Beuren syndrome are highlighted as important examples. A subtle technical point carries real weight here: a normal 25-hydroxyvitamin D level does not exclude impaired vitamin D catabolism, and 1,25-dihydroxyvitamin D results may not be available when early inpatient decisions must be made. Once available, elevated or inappropriately normal 1,25-dihydroxyvitamin D despite suppressed iPTH supports vitamin D-mediated hypercalcemia and may point toward impaired catabolism, renal phosphate-handling defects, or extrarenal 1α-hydroxylase activity.

In older children and adolescents with suppressed iPTH, acquired causes move to the fore: malignancy, immobilization, iatrogenic or drug-induced hypercalcemia, granulomatous infection or inflammation, vitamin A excess, thiazides, and endocrine disorders including thyrotoxicosis and adrenal insufficiency. In children with chronic kidney disease or after transplantation, the iPTH pattern and treatment exposure should guide classification, because treatment-related hypercalcemia may be iPTH independent while persistent or tertiary hyperparathyroidism is iPTH dependent. Parathyroid hormone-related peptide testing may help when malignancy is suspected, though assay and age-related interpretation require caution.

The third pillar—urinary calcium—exists to prevent one of the most consequential errors in this field: misclassifying familial hypocalciuric hypercalcemia (FHH) as primary hyperparathyroidism. FHH is usually mild, lifelong, and often familial, and parathyroidectomy is usually ineffective. Relative hypocalciuria for age and context should therefore prompt family calcium testing and consideration of CASR, GNA11, and AP2S1 genetic testing before localization imaging or surgery. The authors stress that urinary calcium indices are supportive, not diagnostic, and that a spot urine sample for UCa/UCr should be collected within the same clinical time frame as serum calcium and iPTH whenever feasible—asynchronous sampling during hydration, diuretic use, or rapid calcium fluctuation can mislead. Infants normally have higher UCa/UCr than older children, and hydration, sodium intake, renal function, diuretics, and vitamin D status all alter results. Conversely, primary hyperparathyroidism can sometimes appear relatively hypocalciuric, especially with renal dysfunction, low calcium intake, vitamin D deficiency, or thiazide exposure. In neonates with severe hypercalcemia and non-suppressed iPTH, neonatal severe hyperparathyroidism or CASR-related disease should be considered urgently.

Finally, the framework calls for earlier but selective genetic testing. Not every transient mild episode warrants sequencing, but infantile onset, persistent or recurrent hypercalcemia, nephrocalcinosis or nephrolithiasis, family history, syndromic features, or discordant results after common causes are excluded should all accelerate testing. Infantile hypercalcemia with suppressed iPTH supports a panel or exome strategy including vitamin D metabolism and renal phosphate-handling genes such as CYP24A1 and SLC34A1, while non-suppressed iPTH with relative hypocalciuria supports calcium-sensing pathway testing. Dysmorphism, congenital heart disease, developmental delay, or multisystem involvement may require chromosomal microarray or syndrome-directed testing, and early-onset primary hyperparathyroidism, multigland disease, recurrence, parathyroid carcinoma, jaw tumor features, or family history should raise concern for MEN1-, CDC73-, RET-, or CDKN1B-related disease. Variants of uncertain significance, the authors caution, should not be treated as diagnostic without biochemical and segregation support. Because pediatric inpatient hypercalcemia is uncommon, the authors frame their proposal as a starting point, calling for multicenter studies or registry-based audits to test whether structured use of iPTH, age, and urinary calcium genuinely improves diagnostic timeliness, treatment escalation, renal outcomes, avoidance of inappropriate surgery, and hospital stay.

Subject of Research: Triage of pediatric inpatient hypercalcemia using intact parathyroid hormone, age, and urinary calcium

Article Title: Pediatric inpatient hypercalcemia: triage using intact parathyroid hormone, age, and urinary calcium

Article References: Lin, H., Fu, J.-F., & Dong, G.-P. (2026). Pediatric inpatient hypercalcemia: triage using intact parathyroid hormone, age, and urinary calcium. World Journal of Pediatrics. https://doi.org/10.1007/s12519-026-01102-w

Image Credits: AI Generated

DOI: 10.1007/s12519-026-01102-w

Keywords: hypercalcemia, pediatrics, parathyroid hormone, urinary calcium, familial hypocalciuric hypercalcemia, CYP24A1, SLC34A1, vitamin D metabolism, neonatal severe hyperparathyroidism, genetic testing, calcium-sensing pathway, World Journal of Pediatrics

Perivascular spaces are, in healthy brains, almost invisible. They are the cuffs of cerebrospinal fluid that accompany penetrating arteries and veins into the brain’s substance, and in a typical newborn the amount of fluid within them is too small to register on clinical imaging. When these spaces balloon and multiply, however, they show up on T2-weighted magnetic resonance images as bright, linear or round dots, and on FLAIR sequences as dark counterparts of the same shapes. In adults, a heavy burden of enlarged perivascular spaces has been linked to cerebral small vessel disease, cognitive decline, and poor glymphatic clearance of toxic proteins. Until now, almost nothing was known about what these structures mean in the earliest days of life, particularly in babies whose brains have just endured the twin assaults of oxygen deprivation and the inflammatory firestorm that follows it.

The new study, published in the World Journal of Pediatrics, enrolled 319 newborns admitted to the hospital’s neonatology department between January 2020 and September 2023, all transferred within a week of birth. Using strict diagnostic criteria based on Apgar scores and umbilical artery blood gas analysis, the researchers divided the infants into a mild asphyxia group of 229 babies and a severe group of 90. Each child underwent brain magnetic resonance imaging on a 3.0 Tesla scanner, along with amplitude-integrated electroencephalography to capture the electrical rhythms of the injured cortex, and a battery of laboratory tests ranging from inflammatory markers to coagulation profiles. Two experienced radiologists, blinded to all clinical information, counted the enlarged perivascular spaces in the basal ganglia across four to six axial sections, producing a quantitative burden score for every infant.

The results were unambiguous. In the severe asphyxia group, lactate levels and C-reactive protein concentrations were significantly elevated compared with the mild group, and the number of enlarged perivascular spaces was also markedly higher. Across the whole cohort, the count of these spaces correlated positively with diastolic blood pressure and lactate, and negatively with Apgar scores at one, five, and ten minutes. More importantly, when the researchers built multivariable linear regression models to disentangle independent predictors, the number of enlarged perivascular spaces remained significantly associated with the severity of brain injury as graded on a simplified magnetic resonance score, with a P value of 0.0001 across all infants, 0.0248 in the mild group, and 0.0114 in the severe group. This held true even after accounting for gestational age, blood pressure, base excess, Apgar scores, and coagulation measures such as thrombin time and the international normalized ratio.

Intriguingly, the association was selective. The perivascular space count predicted the structural magnetic resonance score but not the amplitude-integrated electroencephalography grade, a measure of acute cortical electrical function. The authors interpret this dissociation as evidence that enlarged perivascular spaces capture structural, glymphatic damage rather than transient functional suppression. Electroencephalographic activity can be temporarily blunted by metabolic derangement and then recover, whereas the magnetic resonance image visualizes established injury to brain parenchyma. A marker of perivascular structural integrity, the researchers argue, aligns more naturally with the latter. This distinction matters clinically, because it suggests the marker adds a dimension of information that neither routine electrophysiology nor blood-based biomarkers of inflammation and neuronal injury can currently provide.

The mechanistic story behind the finding centers on the glymphatic system, the recently characterized network through which cerebrospinal fluid pulses along perivascular channels to flush metabolic waste from the brain, driven in part by the water channel protein aquaporin 4, which is polarized to the endfeet of astrocytes. Asphyxia triggers oxidative stress and a cytokine storm that disrupt this polarization, causing perivascular spaces to enlarge and glymphatic clearance to falter. The consequence may be self-reinforcing: as clearance fails, neurotoxic metabolites accumulate, further amplifying inflammation and astrocytic injury in a vicious cycle of progressive damage. The authors are careful to note that their observational design cannot establish causality; the enlarged spaces may actively contribute to injury or may simply be an epiphenomenon of the same upstream pathology. Either way, their count offers a non-invasive readout of a process that has been nearly impossible to monitor in living newborns.

Perhaps the most provocative result concerns sleep. Because mild asphyxial injury can damage the pineal gland, the source of melatonin, sleep disturbance has long been recognized as a sequela of perinatal asphyxia. The Suzhou team followed 258 of the 319 infants, using monthly parental questionnaires over six months, adapted from the Brief Infant Sleep Questionnaire and the Paediatric Sleep Questionnaire, to score seven sleep problems including prolonged sleep latency, insufficient sleep, irregular schedules, snoring, breathing difficulties, and frequent night wakings. After excluding age as a confounder by stratifying children into three age bands, the researchers found no relationship between perivascular space count and sleep in the full cohort or in the mild group. But in the severe asphyxia group, the correlation was significant: a higher number of enlarged perivascular spaces predicted more severe sleep disturbance, with a Spearman coefficient of 0.3365 and a P value of 0.0061.

That severity-specific pattern, the authors suggest, points to a mechanism beyond direct pineal injury. In severely asphyxiated infants, glymphatic damage may impede the clearance of toxic proteins, perpetuating brain injury and indirectly degrading sleep architecture, whereas in mild cases the perivascular spaces tend to shrink over time as the infant brain repairs itself, explaining the absence of a sleep correlation. The correlation is moderate rather than overwhelming, and the researchers acknowledge that infant sleep is multifactorial and cannot be reduced to a single biomarker. Still, the finding hints that a routine scan performed in the first week of life could flag babies at risk of sleep problems before parents notice anything wrong, opening a window for early behavioral and medical interventions during a period when sleep is critical to brain development.

The study has limitations that the authors confront directly. Ethical constraints precluded a healthy control group, though published data confirm that enlarged perivascular spaces are rare in healthy neonates, and the single-center design, moderate sample size, and reliance on parent-reported sleep questionnaires all warrant caution. The team calls for multicenter prospective cohorts incorporating diffusion tensor imaging along the perivascular space, an advanced technique that quantifies glymphatic flow directly, along with objective sleep monitoring and longitudinal follow-up. If those studies confirm the present findings, the humble perivascular space, long dismissed as an incidental dot on adult brain scans, could become a standard element of neonatal risk stratification, helping clinicians decide which asphyxiated newborns need the most aggressive neuroprotective care and which families should be counseled and monitored for the sleep disorders that may otherwise surface silently in the years after a difficult birth.

Subject of Research: Enlarged perivascular spaces as imaging biomarkers of perinatal asphyxia-induced brain injury and later sleep quality

Article Title: Correlation between perinatal asphyxia-induced brain injury, number of enlarged perivascular spaces, and sleep quality in later life

Article References: Correlation between perinatal asphyxia-induced brain injury, number of enlarged perivascular spaces, and sleep quality in later life. (n.d.). https://doi.org/10.1007/s12519-026-01093-8

Image Credits: AI Generated

DOI: 10.1007/s12519-026-01093-8

Keywords: perinatal asphyxia, enlarged perivascular spaces, glymphatic system, neonatal brain injury, MRI biomarker, sleep quality, hypoxic-ischemic encephalopathy, newborns, aquaporin 4, neonatology, amplitude-integrated EEG, World Journal of Pediatrics

Preoperative anxiety in children is far more than a momentary bout of nerves. Decades of pediatric anesthesia research, including classic work by Vernon and colleagues in the 1960s and the influential studies of Zeev Kain, have documented that anxious children are harder to anesthetize, may require more sedative medication, and are at increased risk of negative behavioral changes after hospitalization, including nightmares, separation difficulties, and new-onset bedtime fears. Estimates suggest that well over half of children undergoing elective surgery experience clinically significant anxiety in the preoperative holding area. Because pharmacologic sedation carries its own risks and costs, nonpharmacologic approaches, from parental presence during anesthesia induction to therapeutic medical play and virtual reality distraction, have become a major focus of pediatric perioperative care research.

The research team, led by Jun-Qing Chen and Wei-Fang Zhang, designed their intervention around what children themselves say they want to know. In an earlier qualitative study of Chinese school-age children awaiting elective surgery, the same group found that children consistently reported gaps in their understanding of what would happen to them: why they needed the operation, what the operating room would look like, whether the surgery would hurt, and when they would see their parents again. Rather than delivering that information through a lecture or a pamphlet, which children often ignore or misinterpret, the researchers embedded it in a card game, allowing children to absorb procedural knowledge through play, repetition, and social interaction with trained facilitators.

The trial enrolled children scheduled for elective surgery and randomly assigned them to either the card game intervention or a usual-care control group. Anxiety was assessed with validated instruments, including the modified Yale Preoperative Anxiety Scale, an observational tool that scores behaviors such as vocalizations, emotional expressivity, state of apparent arousal, and use of parents as a source of comfort, together with self-report measures including Chinese versions of the State-Trait Anxiety Inventory. The researchers report that children in the intervention arm displayed significantly lower anxiety scores than controls in the preoperative period, indicating that the game-based preparation translated into measurably calmer behavior at the point where anxiety typically peaks, immediately before transport to the operating room.

The psychology underlying why a simple card game might outperform standard verbal preparation is rooted in several well-established mechanisms. First, play is the natural language of childhood; children process frightening information more readily when it is presented through symbolic, interactive formats rather than abstract explanations. Second, the game provides cognitive control: by turning the surgical journey into a set of cards to be mastered, questions to be answered, and rounds to be won, it converts a passive, threatening experience into an active, comprehensible one. Third, therapeutic play reduces uncertainty, which is a core driver of anxiety. A child who knows what the anesthesia mask feels like, who will be present, and roughly how long everything will take has fewer unknowns to catastrophize about. Finally, the social dimension matters. Playing with a facilitator or peers engages emotion regulation, normalizes the hospital environment, and gives the child a brief, positive relational experience inside an otherwise intimidating setting.

The findings arrive amid a growing evidence base for game-based interventions in pediatric care. A 2022 systematic review and meta-analysis by Suleiman-Martos and colleagues concluded that game-based interventions significantly reduce preoperative pain and anxiety in children, and a 2023 umbrella review by Agüero-Millan and coauthors found moderate evidence supporting nonpharmacologic interventions more broadly. Other trials have tested incentive-based games, group medical play sessions, and immersive virtual reality, with the latter showing striking results for procedures such as venipuncture. What distinguishes the new study is its simplicity and low cost. A deck of cards requires no screens, no software licenses, no charging infrastructure, and no technical support, making it potentially deployable in resource-limited hospitals and rural clinics where virtual reality headsets are out of reach.

The trial was grounded in the emerging discipline of child life services, which the authors have described elsewhere as the heartbeat of healing in pediatric care. Child life specialists use developmentally appropriate preparation, therapeutic play, and coping support to help children navigate medical experiences, a model that is well established in North America but still developing in many parts of Asia. By demonstrating in a rigorous randomized design that a structured play intervention measurably reduces preoperative anxiety, the Hangzhou team provides local evidence that child life principles can be adapted to the Chinese healthcare context using culturally appropriate materials, potentially accelerating the adoption of psychosocial support services in pediatric units across the region.

Methodologically, the study reflects careful attention to ethics and measurement. It was approved by the Ethics Committee of Children’s Hospital, Zhejiang University School of Medicine, and written informed consent was obtained from parents, with written assent from children aged eight and above and verbal assent from younger children. The use of both observer-rated and self-report anxiety instruments strengthens the findings, since children’s self-assessments and clinician observations can diverge, and converging measures reduce the risk that an apparent benefit reflects measurement artifact. The authors note no conflicts of interest, and the study was funded by the Medical Technology and Education program of Zhejiang Province. The datasets generated in the trial are not publicly available because of privacy and ethical restrictions but can be requested from the corresponding authors.

Like all single-center trials, the study has limits that will shape future work. The sample was drawn from one large children’s hospital, and it remains to be seen whether the same card game performs equally well across different age bands, surgical types, and cultural settings. The trial did not, based on the published report, examine downstream outcomes such as anesthesia induction compliance, postoperative analgesic requirements, or emergence delirium, which are the natural next endpoints for testing whether calmer children before surgery translate into safer and smoother operations afterward. Larger multicenter trials and implementation studies will be needed to determine how the intervention integrates into busy preoperative workflows and whether benefits persist across repeated hospital encounters.

Even so, the message for clinicians and parents is strikingly practical. At a moment when hospitals are investing heavily in digital distraction technology, one of the most effective tools against a child’s fear of surgery may be a deck of cards and twenty minutes of guided play. The intervention requires no anesthesia expertise, can be delivered by nurses or trained volunteers, and costs little enough to be sustainable at scale. For the millions of children who undergo elective surgery worldwide each year, a simple game that helps them understand what is coming may do more than win a round: it may quietly reset one of the most stressful experiences in pediatric medicine, replacing fear with familiarity, one card at a time.

Subject of Research: Effectiveness of a card game-based intervention in reducing preoperative anxiety in children

Article Title: Effectiveness of a card game-based intervention in alleviating preoperative anxiety in children: a randomized controlled trial

Article References: Chen, J.-Q., Sun, R.-Y., Wang, Y., Lin, N., Ye, X., Wang, D., Wu, X.-H., Qiu, F., Xu, H.-Z., & Zhang, W.-F. (2026). Effectiveness of a card game-based intervention in alleviating preoperative anxiety in children: a randomized controlled trial. World Journal of Pediatrics. https://doi.org/10.1007/s12519-026-01097-4

Image Credits: AI Generated

DOI: 10.1007/s12519-026-01097-4

Keywords: preoperative anxiety, children, card game intervention, pediatric surgery, randomized controlled trial, therapeutic play, child life services, pediatric anesthesia, nonpharmacologic intervention, World Journal of Pediatrics, modified Yale Preoperative Anxiety Scale, Zhejiang University

FIRES is a rare and ferocious epileptic encephalopathy that typically announces itself in a previously healthy child. After an ordinary febrile infection, often nothing more sinister than a fever, the child plunges into超 refractory status epilepticus, a prolonged convulsive storm that resists conventional anti-seizure drugs. The syndrome is classified as a subtype of new-onset refractory status epilepticus, or NORSE, and its underlying etiology remains stubbornly unknown. Survivors of the acute phase frequently emerge into a chronic phase marked by drug-resistant epilepsy, cognitive impairment, and profound disability. The condition’s trajectory is so bleak that neurologists have long searched for anything that might bend its course, and growing evidence implicates a runaway neuroinflammatory process, with elevated cytokines detected in the cerebrospinal fluid of affected children.

Among the inflammatory messengers implicated in that storm, interleukin-6 has attracted particular attention. Laboratory and clinical studies have linked higher interleukin-6 signaling to seizure generation and to worse outcomes in NORSE, making the cytokine pathway a logical therapeutic target. Tocilizumab, a monoclonal antibody that binds the interleukin-6 receptor and prevents the cytokine from delivering its signal, is already approved for rheumatoid arthritis and other inflammatory conditions, and international consensus recommendations have endorsed it as an anti-inflammatory option during the acute phase of FIRES. What has been far less clear is whether the drug helps after the acute storm has passed and the child has settled into the chronic, seizure-burdened phase of the illness, when the window for rescuing the brain may seem to have closed.

To answer that question, the Beijing team assembled a retrospective cohort of twenty-seven pediatric patients with chronic-phase FIRES who received tocilizumab. These were children whose epilepsy had already become entrenched: the median duration of seizures at the time the first dose was given was sixteen months, with an interquartile range spanning six to thirty-four months. Over the course of treatment, each patient received a median of four doses of the drug, with a range of three to six. The investigators defined the primary outcome as the response rate at sixteen weeks after initiation, counting as responders those patients whose seizure frequency fell by at least fifty percent. Secondary outcomes included the response rate at twenty-eight weeks, changes in disability measured by the modified Rankin Scale, and treatment-related adverse events.

The results were striking for a syndrome with so few options. After sixteen weeks of tocilizumab, seventeen of the twenty-seven children, or 63 percent, had achieved at least a fifty percent reduction in seizure frequency, and two children, 7.4 percent, became entirely seizure free. Beyond seizure counts, the therapy appeared to change daily life: nineteen of twenty-seven patients, 70.4 percent, showed improvements in their modified Rankin Scale scores, a measure of functional disability. Perhaps equally telling, 81.5 percent of the children, twenty-two of twenty-seven, did not require any additional anti-seizure medications during the entire treatment period, suggesting that the drug’s benefit was not simply an artifact of polytherapy escalation. The benefits, however, were not uniformly durable. By twenty-eight weeks, the response rate had slipped to 48.1 percent, with thirteen of twenty-seven children still maintaining at least a halving of their seizures.

Safety data provided cautious reassurance. The most common adverse event was neutropenia, a depletion of a key class of infection-fighting white blood cells, which occurred in nine patients, or 33.3 percent of the cohort. Infections developed in four patients, 14.8 percent. Neither finding is surprising for a drug that deliberately dampens immune signaling, and both are manageable with monitoring, dose adjustment, and vigilance for early signs of infection. For families weighing the risks of a therapy against the relentless toll of uncontrolled seizures, the profile described in the study suggests that tocilizumab occupies a tolerable middle ground: powerful enough to matter, but not so hazardous that it cannot be given to children over repeated doses.

The study’s authors conclude that tocilizumab is effective in treating the epilepsy of chronic-phase FIRES, reducing seizure frequency in pediatric patients while remaining relatively safe. That conclusion carries weight beyond the twenty-seven patients enrolled. Because FIRES is so rare, randomized controlled trials are extraordinarily difficult to mount, and the field has advanced largely through case reports, small series, and expert consensus. A structured cohort study with predefined endpoints, quantified response rates, functional outcome measures, and systematic adverse-event tracking moves the evidence base a meaningful step forward. It also extends the therapeutic logic of the syndrome itself: if neuroinflammation ignites the acute catastrophe, the same inflammatory circuitry may continue to fuel seizures in the chronic phase, and blocking it can still yield clinical gains even after months of drug resistance.

The road ahead nevertheless demands caution. The study is retrospective, without a randomized control group, so spontaneous fluctuations in seizure burden or concurrent treatment changes cannot be fully excluded as contributors to improvement. The tapering of benefit between sixteen and twenty-eight weeks raises practical questions about dosing intervals, treatment duration, and whether maintenance strategies might consolidate early gains. Identifying which children are most likely to respond, perhaps through cytokine profiling or genetic markers, remains an open frontier. Larger, ideally prospective, multi-center studies will be needed to confirm the findings and to establish where tocilizumab belongs in the treatment algorithm relative to other immunotherapies such as anakinra, which blocks the related interleukin-1 pathway and has also shown promise in chronic-phase FIRES.

For now, the message for clinicians and families is one of tempered optimism. A child with chronic-phase FIRES who has endured more than a year of drug-resistant seizures may still respond to targeted immunotherapy, with nearly two-thirds of treated children in this cohort halving their seizure burden and most improving in functional status. In a field where therapeutic victories are measured in fewer seizures rather than cures, that is no small thing. The Beijing study gives neurologists a firmer evidence platform to offer tocilizumab earlier in the chronic phase, and it hands researchers a clear mandate: define the biology of interleukin-6 signaling in these young brains, and design the trials that will determine how long the benefit lasts.

Subject of Research: Efficacy and safety of tocilizumab, an interleukin-6 receptor antagonist, in treating chronic-phase febrile infection-related epilepsy syndrome in children

Article Title: Efficacy and safety of tocilizumab in the chronic phase of febrile infection-related epilepsy syndrome: a retrospective cohort study

Article References: Liu, W., Zhang, J., Deng, J., Yang, X.-L., Dong, H., Wu, Y., Sang, T., Ji, T.-Y., Zhu, Y., Jiang, Y.-W., & Wu, Y. (2026). Efficacy and safety of tocilizumab in the chronic phase of febrile infection-related epilepsy syndrome: a retrospective cohort study. World Journal of Pediatrics. https://doi.org/10.1007/s12519-026-01065-y

Image Credits: AI Generated

DOI: 10.1007/s12519-026-01065-y

Keywords: tocilizumab, FIRES, febrile infection-related epilepsy syndrome, new-onset refractory status epilepticus, interleukin-6 receptor, pediatric epilepsy, neuroinflammation, immunotherapy, seizure frequency, modified Rankin Scale, retrospective cohort study, World Journal of Pediatrics

The most alarming signal in the accumulating evidence concerns mental health. Recent large-scale surveys of Chinese secondary school students have documented substantial prevalence of depressive and anxiety symptoms, with a 2023 BMC Psychiatry study led by Chen and colleagues identifying a range of associated factors that place enormous numbers of teenagers at risk. A systematic review and meta-analysis published in the Journal of Affective Disorders had already estimated the pooled prevalence of depressive symptoms among secondary school adolescents in mainland China at a level that clinicians describe as a silent epidemic. More recent network analyses, including a 2024 study in General Psychiatry, have mapped how suicidal ideation interlocks with depression and anxiety symptoms among Chinese adolescents, revealing that these conditions are not isolated diagnoses but densely connected webs of distress in which one symptom can amplify and sustain another. For a country where academic competition is intense and psychological support services remain unevenly distributed, the researchers argue, these findings represent a public health emergency in slow motion.

The mechanisms behind this mental health burden are becoming clearer, and they implicate the structure of adolescent daily life itself. Data from the China Family Panel Studies, analyzed by Zhou and colleagues in the International Journal of Environmental Research and Public Health, show that short sleep duration and high academic pressure are both independently associated with depressive symptoms, and that the two frequently compound each other. Chinese adolescents face some of the longest study hours in the world, and the encroachment of schoolwork on sleep has become a defining feature of the teenage years. Meanwhile, sedentary behavior has emerged as a risk factor extending beyond physical health: a 2024 study in Frontiers in Psychiatry reported a relationship between sedentary behavior and non-suicidal self-injury among Chinese adolescents, suggesting that prolonged inactivity may be intertwined with psychological suffering in ways that traditional clinical screening does not capture.

Screens occupy a central place in this shifting risk landscape. A systematic review by Hale and Guan in Sleep Medicine Reviews established that screen time displaces sleep among school-aged children and adolescents, and subsequent research has linked device-specific screen use to physical inactivity and poor eating habits. Studies of problematic internet use, including work published in Psychiatry Investigation, have highlighted gender differences in how adolescents engage with digital platforms and how that engagement spirals into addiction-like patterns. The viewpoint’s authors note that online gambling addiction in mainland China has itself become a recognized clinical challenge, documented in General Psychiatry, adding a further dimension to the digital threats confronting young people. In an era when smartphones reach virtually every teenager, the boundary between technology as a tool and technology as a hazard has become a central battleground for adolescent health policy.

Alongside the mental health crisis, a metabolic one is unfolding. Evidence from seven national school surveys conducted between 1985 and 2019, published in The Lancet Public Health by Song and colleagues, documents persistent and shifting inequalities in thinness and obesity among Chinese children and adolescents. The double burden of malnutrition, where underweight and obesity coexist and often co-occur within the same communities and even the same families, means that nutrition policy cannot be reduced to a single target. A 2026 cross-sectional study from Hangzhou, published in BMJ Paediatrics Open, reported on the prevalence and risk factors of overweight and obesity among children and adolescents in that city, reinforcing the picture of a population whose energy balance has been upended by dietary transition and declining physical activity.

The downstream metabolic consequences are already measurable in pediatric populations. A large-scale cross-sectional study published in Pediatric Diabetes found notable prevalence of impaired fasting glucose among children and adolescents in urban China, pointing to early dysregulation of glucose metabolism that could seed a future epidemic of type 2 diabetes. Hypertension, long considered an adult disease, has been mapped nationally: a systematic review and modelling study in The Lancet Child and Adolescent Health estimated the national, regional, and provincial prevalence of childhood hypertension in China, revealing widespread elevated blood pressure in pediatric populations. These findings carry profound implications, because hypertension and impaired glucose metabolism established in adolescence tend to track into adulthood, converting childhood risk into decades of cardiovascular and metabolic disease.

The authors frame these converging threats as a mismatch between health needs and health systems. China’s pediatric infrastructure, they argue, was largely built around infectious disease, infant mortality, and acute pediatric care, and it excelled at those tasks. But non-communicable diseases now dominate the health needs of Chinese youth, and interventions designed for younger children or for adults do not automatically transfer to adolescents, whose developmental stage, autonomy, and health-seeking behaviors are distinctive. A systematic review in BMJ Paediatrics Open examining implementation factors of non-communicable disease policies and programmes for children and youth in low- and middle-income countries found that translating policy into effective programs remains a persistent weakness, and the authors suggest China is no exception to this global pattern.

There are also grounds for scientific optimism that the authors highlight. The same journal recently published work using integrative metabolomics and machine learning to identify biomarkers of adolescent social anxiety disorder, demonstrating that cutting-edge molecular and computational tools can be directed at conditions that were previously assessed only through subjective questionnaires. Such approaches promise earlier detection and more precise stratification of risk, but the authors caution that technological innovation must be matched by investment in the mundane infrastructure of adolescent health: school-based screening, trained counselors, affordable psychological services, and parental education. Biomarkers alone will not help teenagers who cannot access care, and the viewpoint emphasizes that research advances must feed directly into policy rather than remaining confined to academic journals.

The call to action articulated by He, Xiao, Zhou, and Qiu is deliberately broad. It asks for national attention to adolescent mental health as a priority equal to physical disease, for school and family environments that protect sleep and limit harmful sedentary screen exposure, for nutrition and physical activity policies that address both underweight and obesity, and for surveillance systems capable of tracking rapidly changing adolescent health needs across China’s vast regional inequalities. It also asks pediatricians themselves to evolve, moving beyond the treatment of childhood illness toward the promotion of lifelong health trajectories that begin in the teenage years. The paper was funded by the Guangzhou Health Science and Technology Project, and the authors state that the funder played no role in the design or content of the manuscript. As China’s adolescents confront a world of academic pressure, digital saturation, and obesogenic environments, the message from Guangzhou is unambiguous: the systems that saved their lives as infants must now be reinvented to protect their futures as adults.

The timing of the viewpoint reflects a broader recalibration in global child health thinking. For much of the twentieth century, pediatric progress was measured in survival metrics, and China’s dramatic reductions in infant and child mortality stand among the most celebrated achievements in public health history. Yet as mortality has fallen, morbidity has migrated toward conditions that are chronic, cumulative, and behavioral in origin, which resist the single-dose interventions, such as vaccination campaigns, that served the previous era so well. Adolescent health occupies an awkward institutional middle ground: too old for pediatric services oriented toward early childhood, too young for adult medicine, and frequently overlooked by both.

The developmental science underlying this argument is well established. Adolescence is a period of profound neuroplasticity, during which reward circuitry matures ahead of regulatory control, heightening sensitivity to stress, sleep deprivation, and the persuasive design of digital environments. This makes the teenage years both a period of heightened vulnerability and a window of unusual opportunity, since health behaviors related to diet, activity, sleep, and substance use established during adolescence tend to persist across the life course. Interventions delivered in this window can therefore yield returns that compound over decades, a point the authors implicitly invoke when they urge pediatricians to think in terms of lifelong health trajectories.

The regional heterogeneity of China adds a further layer of complexity. With enormous variation in income, urbanization, and access to services across provinces, a uniform national policy risks being simultaneously too weak for high-burden areas and poorly matched to others. The authors’ emphasis on surveillance systems capable of tracking changing needs reflects this reality: without granular, regularly updated data on adolescent mental health, nutrition, and cardiometabolic risk, policymakers cannot direct resources where they are most needed, and the gap between evidence and action will continue to widen.

Subject of Research: A call to action on emerging physical and mental health challenges among adolescents in China.

Article Title: Emerging challenges and call to action for adolescent health in China

Article References: He, J.-R., Xiao, W.-Q., Zhou, W.-H., & Qiu, X. (2026). Emerging challenges and call to action for adolescent health in China. World Journal of Pediatrics. https://doi.org/10.1007/s12519-026-01074-x

Image Credits: AI Generated

DOI: 10.1007/s12519-026-01074-x

Keywords: adolescent health, China, mental health, depression, obesity, sleep duration, screen time, academic pressure, childhood hypertension, public health policy, noncommunicable diseases, World Journal of Pediatrics